Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin
Autor: | Donna E. Hogge, Stephen A. Strickland, Geoffrey L. Uy, Arthur C. Louie, Jorge E. Cortes, Jeffrey E. Lancet, Jonathan E. Kolitz, Stuart L. Goldberg, Michael Chiarella, Robert J. Ryan |
---|---|
Rok vydání: | 2018 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty business.industry Daunorubicin Phases of clinical research Hematology Newly diagnosed 03 medical and health sciences 0302 clinical medicine Older patients 030220 oncology & carcinogenesis Internal medicine medicine Cytarabine Secondary Acute Myeloid Leukemia business 030217 neurology & neurosurgery medicine.drug |
Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 18:S208-S209 |
ISSN: | 2152-2650 |
Databáze: | OpenAIRE |
Externí odkaz: |